We examined the in vitro antiproliferative activity of BCL2-selective inhibitors in a wide range of lymphoma cell lines, including DLBCL, mantle cell lymphoma (MCL), Hodgkin lymphoma (HL), Burkitt lymphoma (BL), and anaplastic large cell lymphoma. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.